US Bancorp DE Purchases 12,627 Shares of Hologic, Inc. (NASDAQ:HOLX)

US Bancorp DE boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 34.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,011 shares of the medical equipment provider’s stock after purchasing an additional 12,627 shares during the quarter. US Bancorp DE’s holdings in Hologic were worth $3,968,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Edmond DE Rothschild Holding S.A. increased its holdings in Hologic by 12.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,296 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 139 shares during the last quarter. Belpointe Asset Management LLC grew its stake in Hologic by 18.0% in the first quarter. Belpointe Asset Management LLC now owns 937 shares of the medical equipment provider’s stock valued at $76,000 after acquiring an additional 143 shares during the period. FineMark National Bank & Trust grew its stake in Hologic by 4.1% in the first quarter. FineMark National Bank & Trust now owns 3,824 shares of the medical equipment provider’s stock valued at $309,000 after acquiring an additional 149 shares during the period. Cypress Capital Group grew its stake in Hologic by 1.0% in the first quarter. Cypress Capital Group now owns 16,123 shares of the medical equipment provider’s stock valued at $1,301,000 after acquiring an additional 154 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Hologic by 0.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 21,335 shares of the medical equipment provider’s stock valued at $1,727,000 after acquiring an additional 158 shares during the period. Institutional investors own 92.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HOLX. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, November 10th. Bank of America decreased their price objective on Hologic from $94.00 to $86.00 and set a “neutral” rating for the company in a report on Tuesday, August 1st. Raymond James decreased their price objective on Hologic from $95.00 to $85.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Citigroup decreased their price objective on Hologic from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Tuesday, August 1st. Finally, Royal Bank of Canada decreased their price objective on Hologic from $74.00 to $72.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.58.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $71.90 on Tuesday. The company has a current ratio of 3.47, a quick ratio of 2.95 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The stock has a 50 day moving average of $69.42 and a 200-day moving average of $75.31. The company has a market capitalization of $17.61 billion, a P/E ratio of 39.29, a P/E/G ratio of 2.34 and a beta of 1.03.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, November 9th. The medical equipment provider reported $0.89 EPS for the quarter, topping the consensus estimate of $0.84 by $0.05. Hologic had a return on equity of 19.12% and a net margin of 11.31%. The company had revenue of $945.30 million during the quarter, compared to the consensus estimate of $940.00 million. During the same period in the previous year, the company posted $0.82 EPS. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. As a group, equities research analysts predict that Hologic, Inc. will post 3.99 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.